Work

Safety of 177Lu-DOTATATE administration in a patient with recurrent meningioma complicated by radiation necrosis: a case report

Year: 2024

Type: article

Abstract: Radiation-associated meningiomas are characterized by high rates of recurrence. 177 Lu-DOTATATE may represent a treatment option for these tumors, but safety of this agent for patients with a history of radiation necrosis is unknown. In this case report, we describe the preliminary safety of 177 Lu-DOTATATE administration for a patient with prior history of radiation necrosis. The patient was diagnosed with central nervous system (CNS) germinoma at age 17, managed with chemoradiation. Twenty years later, a left-parietal extra-axial mass was identified within the prior radiation field, with diagnosis of atypical meningioma established on subtotal resection. He received additional radiation therapy (RT, 60 Gy, 30 fractions). Seventeen months later, tumor progression was treated with gamma knife radiosurgery (GKRS, 15 Gy, single fraction). Seven months after GKRS, seizures recurred, with imaging consistent with radiation necrosis. The patient was treated with bevacizumab (7.5 mg/kg, every 3 weeks, 4 doses). One year later, magnetic resonance imaging (MRI) brain revealed tumor progression within the treatment field. 68 Ga-DOTATATE positron emission tomography demonstrated that the meningioma was DOTATATE-avid with no evidence of metastasis. The patient was treated with 177 Lu-DOTATATE (two infusions, two months apart), which was well tolerated with no significant toxicities and no recurrence of radiation necrosis. Two months after the second infusion, the patient experienced disease progression and was transitioned to bevacizumab. In this patient with three prior courses of intracranial radiation and subsequent radiation necrosis, 177 Lu-DOTATATE was well-tolerated. 177 Lu-DOTATATE administration may be feasible for patients with a history of radiation necrosis.

Source: Discover Medicine

DOI: 10.1007/s44337-024-00095-7